[Studies on compatibility of tretinoin following systemic and topical application. 1. Toxicological studies].
D000152:Acne Vulgaris / Q000188:drug therapy; D000284:Administration, Oral; D000287:Administration, Topical; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001786:Blood Glucose; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004361:Drug Tolerance; D004487:Edema / Q000139:chemically induced; D004890:Erythema / Q000139:chemically induced; D004912:Erythrocytes / Q000187:drug effects; D005123:Eye / Q000187:drug effects; D005260:Female; D005782:Gels; D006454:Hemoglobins / Q000187:drug effects; D007274:Injections, Intraperitoneal; D007928:Lethal Dose 50; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D051379:Mice; D011517:Prothrombin Time; D011817:Rabbits; D051381:Rats; D012867:Skin / Q000187:drug effects; D013535:Suspensions; D014801:Vitamin A / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity
D001786:Blood Glucose; D005782:Gels; D006454:Hemoglobins; D013535:Suspensions; D014801:Vitamin A; D000469:Alkaline Phosphatase
Untersuchungen zur Verträglichkeit von Tretinoin nach systemischer und lokaler Applikation 1. Mitteilung: Toxikologische Untersuchungen